Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 5/20 | 0.37 |
| ▸ | SCD | O00767 | 4/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021209 | 0.83 | CYP1A2 (0.53) | LMNAHTTCNR2 | |
| SCHEMBL2421817 | 0.80 | BPTF (0.56) | LMNAHTT | |
| SCHEMBL607319 | 0.80 | CNR2 (0.56) | LMNAHTTCNR2KMO | |
| SCHEMBL64557 | 0.80 | NPC1 (0.47) | LMNAHTTDCTPP1SCD | |
| Hydrochloric Acid SCHEMBL30263381 | 0.79 | CNR2 (0.55) | LMNAHTTCNR2KMO | |
| SCHEMBL15754487 | 0.79 | LMNA (0.50) | LMNAHTTCNR2DCTPP1SCD | |
| SCHEMBL24620129 | 0.78 | BPTF (0.54) | SCD | |
| SCHEMBL1814804 | 0.78 | LMNA (0.49) | LMNAHTTCNR2DCTPP1SCD | |
| SCHEMBL4440043 | 0.76 | HRH3 (0.46) | DCTPP1SCD | |
| SCHEMBL2944404 | 0.76 | NPC1 (0.46) | LMNAHTTDCTPP1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-111825657-A | Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof | 成都海创药业有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091225-A1 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | AR, ADRM1, PSMA1 | LMNA 3055/4885HTT 2931/4885CNR2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.